Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system

Marxa L. Figueiredo, Makoto Sato, Mai Johnson, Lily Wu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Significant advances in gene therapy have been made as a result of the improvement of gene delivery systems, discovery of new therapeutic genes, better understanding of mechanisms of disease progression, exploration and improvement of tissue-specific gene regulatory sequences, and development of better prodrug/enzyme systems. This review discusses adenoviral-based and prostate-specific cancer gene therapy - emphasizing tissue-specific promoter choices to increase gene therapy safety and specificity - and the development of prostate-targeted vectors, with a focus on the two-step transactivation system for amplifying gene expression, specifically in prostate cancer cells. Several examples will be discussed for the scientific basis and therapeutic applications. In addition, prostate cancer gene therapy clinical trials and future directions in this field will also be described briefly.

Original languageEnglish (US)
Pages (from-to)391-406
Number of pages16
JournalFuture Oncology
Volume2
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Genetic Therapy
Prostatic Neoplasms
Neoplasm Genes
Gene Transfer Techniques
Prodrugs
Regulator Genes
Transcriptional Activation
Disease Progression
Prostate
Clinical Trials
Safety
Gene Expression
Enzymes
Therapeutics
Genes

Keywords

  • Prostate cancer
  • Tissue-specific gene expression
  • Two step transcriptional amplification system
  • Viral based gene therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system. / Figueiredo, Marxa L.; Sato, Makoto; Johnson, Mai; Wu, Lily.

In: Future Oncology, Vol. 2, No. 3, 06.2006, p. 391-406.

Research output: Contribution to journalArticle

Figueiredo, Marxa L. ; Sato, Makoto ; Johnson, Mai ; Wu, Lily. / Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system. In: Future Oncology. 2006 ; Vol. 2, No. 3. pp. 391-406.
@article{7ac6597745d94f34850c775b65b7f500,
title = "Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system",
abstract = "Significant advances in gene therapy have been made as a result of the improvement of gene delivery systems, discovery of new therapeutic genes, better understanding of mechanisms of disease progression, exploration and improvement of tissue-specific gene regulatory sequences, and development of better prodrug/enzyme systems. This review discusses adenoviral-based and prostate-specific cancer gene therapy - emphasizing tissue-specific promoter choices to increase gene therapy safety and specificity - and the development of prostate-targeted vectors, with a focus on the two-step transactivation system for amplifying gene expression, specifically in prostate cancer cells. Several examples will be discussed for the scientific basis and therapeutic applications. In addition, prostate cancer gene therapy clinical trials and future directions in this field will also be described briefly.",
keywords = "Prostate cancer, Tissue-specific gene expression, Two step transcriptional amplification system, Viral based gene therapy",
author = "Figueiredo, {Marxa L.} and Makoto Sato and Mai Johnson and Lily Wu",
year = "2006",
month = "6",
doi = "10.2217/14796694.2.3.391",
language = "English (US)",
volume = "2",
pages = "391--406",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system

AU - Figueiredo, Marxa L.

AU - Sato, Makoto

AU - Johnson, Mai

AU - Wu, Lily

PY - 2006/6

Y1 - 2006/6

N2 - Significant advances in gene therapy have been made as a result of the improvement of gene delivery systems, discovery of new therapeutic genes, better understanding of mechanisms of disease progression, exploration and improvement of tissue-specific gene regulatory sequences, and development of better prodrug/enzyme systems. This review discusses adenoviral-based and prostate-specific cancer gene therapy - emphasizing tissue-specific promoter choices to increase gene therapy safety and specificity - and the development of prostate-targeted vectors, with a focus on the two-step transactivation system for amplifying gene expression, specifically in prostate cancer cells. Several examples will be discussed for the scientific basis and therapeutic applications. In addition, prostate cancer gene therapy clinical trials and future directions in this field will also be described briefly.

AB - Significant advances in gene therapy have been made as a result of the improvement of gene delivery systems, discovery of new therapeutic genes, better understanding of mechanisms of disease progression, exploration and improvement of tissue-specific gene regulatory sequences, and development of better prodrug/enzyme systems. This review discusses adenoviral-based and prostate-specific cancer gene therapy - emphasizing tissue-specific promoter choices to increase gene therapy safety and specificity - and the development of prostate-targeted vectors, with a focus on the two-step transactivation system for amplifying gene expression, specifically in prostate cancer cells. Several examples will be discussed for the scientific basis and therapeutic applications. In addition, prostate cancer gene therapy clinical trials and future directions in this field will also be described briefly.

KW - Prostate cancer

KW - Tissue-specific gene expression

KW - Two step transcriptional amplification system

KW - Viral based gene therapy

UR - http://www.scopus.com/inward/record.url?scp=33745509594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745509594&partnerID=8YFLogxK

U2 - 10.2217/14796694.2.3.391

DO - 10.2217/14796694.2.3.391

M3 - Article

VL - 2

SP - 391

EP - 406

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -